NCT00190411View on ClinicalTrials.gov

Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type

PHASE4CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANTCHROMOSOME 2q31.2 DELETION SYNDROME

Interventions

DRUG

celiprolol

celiprolol

DRUG

Control

Untreated controls excluding betablockers

Sponsors

Collaborators (1)

Aventis Pharmaceuticals

All Listed Sponsors

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER